0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Epidemiología y salud pública en la epidemia de la COVID-19 Translated title: Epidemiology and public health in the COVID-19 epidemic

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          En este último año, todos hemos sufrido las devastadoras consecuencias de la epidemia por SARS-CoV2. En unos meses, los medios de comunicación nos han bombardeado con mensajes sobre incidencias, letalidad o incluso medidas más técnicas como el R0 o la tasa de ataque. Con esta actualización se pretende aclarar los conceptos básicos sobre la dinámica de la epidemia, así como exponer lo que, hasta la fecha en que se escribe, se conoce de la misma. Para ello, se ha utilizado y extraído la información disponible en organismos internacionales como la Organización Mundial de la Salud, así como en el Ministerio de Sanidad. En ningún caso se ha de entender como una situación fija o conocida. Una situación que, por otro lado, invariablemente ha de ser cambiante.

          Translated abstract

          In the last year, all have suffered the devastating consequences of the SARS-CoV-2 epidemic. Over the course of a few months, the news media has bombarded us with messages about incidences, lethality, or even more technical measurements such as R0 or the attack rate. With this update, we hope to clarify basic concepts on the dynamic of the epidemic as well as present what is known about it as of the time of writing. To do so, the information available from international bodies such as the World Health Organization as well as the Ministry of Health has been extracted and used. In no case is it to be understood as a fixed or known situation; it is a situation that, in contrast, is invariably changeable.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

          Summary Background Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic. Methods The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. We planned a series of 12 consecutive weekly serosurveys among randomly selected participants from a previous population-representative survey, and their household members aged 5 years and older. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. We estimated seroprevalence using a Bayesian logistic regression model taking into account test performance and adjusting for the age and sex of Geneva's population. Here we present results from the first 5 weeks of the study. Findings Between April 6 and May 9, 2020, we enrolled 2766 participants from 1339 households, with a demographic distribution similar to that of the canton of Geneva. In the first week, we estimated a seroprevalence of 4·8% (95% CI 2·4–8·0, n=341). The estimate increased to 8·5% (5·9–11·4, n=469) in the second week, to 10·9% (7·9–14·4, n=577) in the third week, 6·6% (4·3–9·4, n=604) in the fourth week, and 10·8% (8·2–13·9, n=775) in the fifth week. Individuals aged 5–9 years (relative risk [RR] 0·32 [95% CI 0·11–0·63]) and those older than 65 years (RR 0·50 [0·28–0·78]) had a significantly lower risk of being seropositive than those aged 20–49 years. After accounting for the time to seroconversion, we estimated that for every reported confirmed case, there were 11·6 infections in the community. Interpretation These results suggest that most of the population of Geneva remained uninfected during this wave of the pandemic, despite the high prevalence of COVID-19 in the region (5000 reported clinical cases over <2·5 months in the population of half a million people). Assuming that the presence of IgG antibodies is associated with immunity, these results highlight that the epidemic is far from coming to an end by means of fewer susceptible people in the population. Further, a significantly lower seroprevalence was observed for children aged 5–9 years and adults older than 65 years, compared with those aged 10–64 years. These results will inform countries considering the easing of restrictions aimed at curbing transmission. Funding Swiss Federal Office of Public Health, Swiss School of Public Health (Corona Immunitas research program), Fondation de Bienfaisance du Groupe Pictet, Fondation Ancrage, Fondation Privée des Hôpitaux Universitaires de Genève, and Center for Emerging Viral Diseases.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland

            The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen and is key to characterising the severity of infection across the population and for specific demographic groups. To date, few empirical estimates of the IFR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been published owing to challenges in measuring infection rates.1, 2 Outside of closed, closely observed populations where infection rates can be monitored through viral surveillance, we must rely on indirect measures of infection, such as antibodies. Representative seroprevalence studies provide an important opportunity to estimate the number of infections in a community, and when combined with death counts can lead to robust estimates of the IFR. We estimated overall and age-specific IFRs for the canton of Geneva, Switzerland, using age-stratified daily case and death incidence reports combined with population-based seroprevalence estimates done each week for 5 consecutive weeks (table ). 3 From Feb 24, to June 2, 2020, there were 5039 confirmed cases of COVID-19 and 286 reported deaths within Geneva (population of 506 765). We inferred age-stratified (5–9 years, 10–19 years, 20–49 years, 50–64 years, and ≥65 years) IFRs by linking the observed number of deaths to the estimated number of infected individuals from each serosurvey. We account for the delays between infection and seroconversion, as well as between infection and death (including deaths that had not yet been observed at the time of the analyses). 4 Inference is drawn in a Bayesian framework that incorporates uncertainty in seroprevalence estimates (appendix p 3). Table Age-stratified estimates of the IFR of SARS-CoV-2 in the canton of Geneva, Switzerland Population Seroconverted population as of May 6 (95% CrI) Deaths as of June 1 IFR (95% CrI), % 5–9 years 26 466 1200 (400–2400) 0 0·0016 (0 to 0·019) 10–19 years 53 180 6100 (3900–8800) 0 0·00032 (0 to 0·0033) 20–49 years 219 440 28 800 (21 400–37 300) 2 0·0092 (0·0042 to 0·016) 50–64 years 98 528 10 300 (7200–13 900) 16 0·14 (0·096 to 0·19) ≥65 years 83 574* 5700 (3200–8800) 268 5·6 (4·3 to 7·4) All 506 765 54 800 (41 300–70 700) 286 0·64 (0·38 to 0·98) CrI=credible interval. IFR=infection fatality risk. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. * Of whom approximately 4065 (4·9%) live in assisted care facilities. Of the 286 reported deaths caused by SARS-CoV-2, the youngest person to die was 31 years old. Infected individuals aged 20–49 years had an IFR of 0·0092% (95% credible interval 0·0042–0·016; one in 10 870 risk of death), with the IFR increasing to 0·14% (0·096–0·19) for those aged 50–64 years and to 5·6% (4·3–7·4) for those aged 65 years and older. After accounting for demography and age-specific seroprevalence, we estimated a population-wide IFR of 0·64% (0·38–0·98; table). Our results are subject to two notable limitations. Of 268 individuals aged 65 years and older who died, 134 (50%) were residents of assisted care facilities, where around 0·8% of the Geneva population resides. Although the serosurvey protocol did not explicitly exclude these individuals, they are likely to have been absent or severely under-represented. This under-representation would lead to an overestimation of the IFR in the 65 years and older age group if seroprevalence in this institutionalised population was higher than in the general population of the same age (appendix p 6). Furthermore, our IFR estimates are based on existing evidence regarding post-infection antibody kinetics, which might differ between severe and mild infections. If mild infections have substantially lower and short-lived antibody responses, our estimates of the IFR might be biased upwards. 5 Estimates of the IFR are key to understanding the true pandemic burden and for comparing different risk-reduction strategies. The IFR is not solely determined by host and pathogen biology, but also by the capacity of health systems to treat severe cases. Despite having among the highest per-capita incidence of confirmed COVID-19 in Switzerland, Geneva's health system, with additional COVID-19 surge capacity, accommodated the influx of cases needing intensive care (peak of 80 of 110 surge capacity intensive care unit beds were in use at one time) while maintaining care quality standards. As such, our IFR estimates can be seen as a best-case scenario with respect to health system capacity. Our results reveal that population-wide estimates of IFR mask great heterogeneity by age and point towards the importance of age-targeted interventions to reduce exposures among those at highest risk of death.
              Bookmark
              • Record: found
              • Abstract: not found
              • Book Chapter: not found

              Diccionario de la lengua española. 23ª ed

                Bookmark

                Author and article information

                Journal
                Medicine (Madr)
                Medicine (Madr)
                Medicine
                Elsevier Espana
                0304-5412
                1578-8822
                24 December 2020
                December 2020
                24 December 2020
                : 13
                : 23
                : 1297-1304
                Affiliations
                [a ]Departamento de Cirugía, Ciencias Médicas y Sociales
                [b ]Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, Madrid, España
                Author notes
                [* ]Autor para correspondencia.
                Article
                S0304-5412(20)30310-3
                10.1016/j.med.2020.12.011
                7759347
                33390643
                de24eec0-b5d3-49fd-9546-d01aa1df8aa0
                .

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Actualización

                epidemiología,medicina preventiva,salud pública,covid-19,epidemiology,preventative medicine,public health

                Comments

                Comment on this article